Quest Diagnostics Incorporated (DGX)

NYSE: DGX · USD

$236

+4.10 (+1.8%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-07-29 02:00 UTC. Latest published research analyzed 2026-05-13 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh DGX analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-13

Our latest published analysis: DGX rated Buy

Buy. Shares trade at a discount to our $226.02 fair value midpoint, offering defensive compounding and structural free cash flow yield.

Fair value (mid)

$226 / share

$185 – $268

Upside to FV

+18.9%

from $236

Confidence

88/100

Moat

6.5/10

Read full analysis

Market cap	$21.1B
Revenue (ttm)	11.6B
Net income (ttm)	1.1B
EPS (ttm)	$9.42
Shares out	110.4M
P/E (trailing)	25.1x
P/E (forward)	16.3x
Dividend	$3.44 (1.48%)
Volume	1,611,015
Beta	0.57
Price target	$242	+2.7%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11.6B
Net income (ttm): 1.1B
EPS (ttm): $9.42
P/E (trailing): 25.1x
P/E (forward): 16.3x
Market cap: $21.1B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$10.79B	$9.88B	$9.25B	$9.87B	$11.04B	+0.6%
Gross profit	$4.21B	$3.43B	$3.05B	$3.24B	$3.67B	-3.4%
Operating income	$2.38B	$1.43B	$1.26B	$1.35B	$1.56B	-10.1%
Net income	$2.00B	$946.0M	$854.0M	$871.0M	$992.0M	-16.0%
EPS (diluted)	$15.55	$7.97	$7.49	$7.69	$8.75	-13.4%
EBITDA	$3.16B	$1.82B	$1.73B	$1.89B	$2.17B	-9.0%
R&D	—	—	—	—	—	—
SG&A	$1.73B	$1.87B	$1.64B	$1.77B	$1.97B	+3.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	465.2B	129.7x	7.4x	14.4%	+4.6%	+44.0%	Hold
ABT	Abbott Laboratories	186.9B	34.9x	4.0x	7.9%	+3.0%	-12.5%	Strong Buy
ACN	Accenture plc	106B	13.9x	1.4x	27.1%	+8.8%	-35.4%	Buy
AMGN	Amgen Inc.	209.2B	27.0x	5.6x	19.1%	+8.1%	+32.5%	Strong Buy
BIIB	Biogen Inc.	30.9B	37.1x	3.1x	7.7%	-3.0%	+61.8%	Strong Buy
BMY	Bristol-Myers Squibb Company	128.9B	17.7x	2.7x	20.9%	+2.5%	+39.2%	Strong Buy

All DGX indicators

Market & fundamental data

Available fields

293

Groups with data

Currency

USD

Showing 293 of 293 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001022079
Company name	Quest Diagnostics Incorporated
Country	United States
Country code	US
Cusip	74834L100
Employees	57,000
Employees Change	1,000%
Employees Change Percent	1.79
Enterprise value	$31.8B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Diagnostics & Research
Industry PE	42.83
Industry PE Fwd	25.86
IPO Date	1996-12-17
Isin	US74834L1008
Last refreshed	2026-07-29
Market cap	$26B
Market cap category	Large-Cap
Price	$236
Price currency	USD
Rev Per Employee	202,807.02x
Sector	Healthcare
Sector PE	45.13
Sector PE Fwd	23.9
Sic	8071
Symbol	DGX
Website	https://www.questdiagnostics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.06%
EV Earnings	30.08x
EV Sales Forward	2.6x
EV/EBIT	19.52x
EV/EBITDA	13.5x
EV/FCF	23.59x
EV/Sales	2.75x
FCF yield	5.18%
Forward P/E	20.66x
P/B ratio	3.45x
P/E ratio	25.06x
P/S ratio	2.25x
PE Ratio10 Y	16.98x
PE Ratio3 Y	19.94x
PE Ratio5 Y	17.39x
PEG ratio	2.18x
PS Forward	2.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	14.1%
EBITDA Margin	20.39%
FCF margin	11.67%
Gross margin	33.19%
Gross Profit	$3.8B
Gross Profit Growth	9.72%
Gross Profit Growth Q	8.9%
Gross Profit Growth3 Y	5.97%
Gross Profit Growth5 Y	-3.63%
Net Income	$1.1B
Net Income Growth	11.79%
Net Income Growth Q	13.48%
Net Income Growth Quarters	8%
Net Income Growth Years	2%
Net Income Growth3 Y	10.23%
Net Income Growth5 Y	-13.92%
Pretax Margin	12.4%
Profit Margin	9.19%
Profit Per Employee	$18,561
Profitable Quarters	$61
Profitable Years	26
ROA	6.4
Roa5y	7.22
ROCE	10.76
ROE	14.6
Roe5y	18.06
ROIC	9.55
Roic5y	11.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.05%
Cagr15y	12.43%
Cagr1y	42.47%
Cagr20y	8.91%
Cagr3y	23.03%
Cagr5y	13.19%
Div CAGR10	7.85%
Div CAGR3	6.61%
Div CAGR5	7.06%
EPS Growth	12.83
EPS Growth Q	14.98
EPS Growth Quarters	8
EPS Growth Years	2
EPS Growth3 Y	11.02
EPS Growth5 Y	-10.84
FCF Growth	10.21%
FCF Growth Q	5.28%
FCF Growth3 Y	15.39%
FCF Growth5 Y	-9.08%
OCF Growth	13.41%
OCF Growth Q	9.74%
OCF Growth10 Y	7.22%
OCF Growth3 Y	11.47%
OCF Growth5 Y	-6.01%
Revenue Growth	9.87x
Revenue Growth Q	10.21x
Revenue Growth Quarters	10x
Revenue Growth Years	2x
Revenue Growth3 Y	6.81x
Revenue Growth5 Y	0.89x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.7
Assets	$16.9B
Cash	$626M
Current Assets	$2.8B
Current Liabilities	$1.8B
Debt	$6.4B
Debt EBITDA	$2.72
Debt Equity	$0.81
Debt FCF	$4.75
Equity	$7.9B
Interest Coverage	6.06
Liabilities	$9B
Long Term Assets	$14.1B
Long Term Liabilities	$7.3B
Net Cash	$-5.8B
Net Cash By Market Cap	$-22.19
Net Debt EBITDA	$2.45
Net Debt Equity	$0.73
Net Debt FCF	$4.28
Tangible Book Value	$-3.3B
Tangible Book Value Per Share	$-29.71
WACC	6.58

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.59
Inventory Turnover	36.78
Net Working Capital	$620M
Quick ratio	1.28
Working Capital	$1.1B
Working Capital Turnover	$18.8

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.88%
Dividend Growth	7.1%
Dividend Growth Years	14%
Dividend per share	$3.44
Dividend Years	23
Dividend Yield	1.48%
Ex Div Date	2026-07-08
Last Dividend	$0.86
Payout Frequency	Quarterly
Payout Ratio	35.26%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	241.03%
1Y total return	42.44%
200-day SMA	193.3
3Y total return	86.24%
50-day SMA	204.2
50-day SMA vs 200-day SMA	50over200
5Y total return	85.78%
All Time High	240.1
All Time High Change	-1.74%
All Time High Date	2026-07-28
All Time Low	3.31
All Time Low Change	7,021.64%
All Time Low Date	1996-12-18
ATR	7.02
Beta	0.57
Beta1y	-0.47
Beta2y	0.04
Ch YTD	35.97
High	240.1
High52	240.1
High52 Date	2026-07-28
High52ch	-1.74%
Low	234
Low52	165.8
Low52 Date	2025-07-28
Low52ch	42.32%
Ma50ch	15.54%
Premarket Change Percent	0.22
Premarket Price	$232
Premarket Volume	229
Price vs 200-day SMA	22.08%
RSI	76.71
RSI Monthly	69.14
RSI Weekly	74.97
Sharpe ratio	1.44x
Sortino ratio	2.84
Total Return	2.34%
Tr YTD	37.74
Tr15y	479.95%
Tr1m	12.87%
Tr1w	14.07%
Tr3m	20.48%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	18
Analyst Count Top	8
Analyst Price Target Top	$250
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$2.82
Earnings EPS Estimate Growth	7.63
Earnings Revenue Estimate	2,974,764,384x
Earnings Revenue Estimate Growth	7.74x
Operating Income	$1.7B
Operating Income Growth	10.99
Operating Income Growth Q	8.67
Operating Income Growth3 Y	8.91
Operating Income Growth5 Y	-10.11
Operating margin	14.58
Price target	$242
Price Target Change	$2.73
Price Target Change Top	$6.08

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	109,795,942%
Float Percent	99.48%
Net Borrowing	-8,000,000
Shares Insiders	0.38%
Shares Institutions	96.67%
Shares Out	110,373,360
Shares Qo Q	0%
Shares Yo Y	-0.88%
Short Float	3.2%
Short Ratio	3.89
Short Shares	3.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$1.3B
Adjusted OCF	1,815,000,000
Average Volume	1,114,726.6x
Bv Per Share	68.33
CAPEX	$-554M
Ch10y	179.8
Ch15y	333.6
Ch1m	12.42
Ch1w	14.07
Ch1y	39.98
Ch20y	296.5
Ch3m	19.99
Ch3y	75.6
Ch5y	68.58
Ch6m	28.06
Change	1.77%
Change From Open	0.32
Close	231.8
Days Gap	1.44
Depreciation Amortization	580,000,000
Dollar Volume	380,102,879.1
Earnings Date	2026-07-23
Earnings Time	bmo
EBIT	$1.6B
EBITDA	$2.4B
EPS	$9.42
F Score	5
FCF	$1.3B
FCF EV Yield	4.24x
FCF Per Share	$12.22
Financing CF	-915,000,000
Fiscal Year End	December
Founded	1,967
Goodwill	9,112,000,000
Graham Number	120.32003
Graham Upside	-49
Income Tax	$320M
Investing CF	-678,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-23
Last Report Date	2026-06-30
Last Split Date	2005-06-21
Last Split Type	Forward
Last10k Filing Date	2026-02-26
Lynch Fair Value	$47.08
Lynch Upside	-80.04
Ma150	196.6
Ma150ch	20.02%
Ma20	213.8
Ma20ch	10.35%
Net CF	307,000,000
Next Earnings Date	2026-10-20
Open	235.2
Optionable	Yes
P FCF Ratio	19.3
P FCF Ratio SBC	20.65
P OCF Ratio	13.68
P OCF Ratio SBC	14.35
Payment Date	2026-07-22
Position In Range	31.87
Post Close	235.9
Postmarket Change Percent	0.97
Postmarket Price	$238
Ppne	2,897,000,000
Pre Close	231.8
Price Date	2026-07-28
Price EBITDA	$11.05
Relative Volume	1.45x
Revenue	11,560,000,000x
SBC By Revenue	0.76x
Share Based Comp	88,000,000
Tax By Revenue	2.77x
Tax Rate	22.33%
Tr20y	450.79%
Tr6m	29.14%
Us State	New Jersey
Volume	1,611,015
Z Score	3.32

Frequently asked questions

About this DGX report

What is the latest published DGX stock rating?

Quest Diagnostics Incorporated is shown with buy in the latest published report, analyzed 2026-05-13. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DGX analysis?

The full latest published report, analyzed 2026-05-13, lives at /stocks/DGX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for DGX?

The latest published report analyzed 2026-05-13 frames DGX around USD 185 to USD 268. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the DGX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-13). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Quest Diagnostics Incorporated (DGX)

Coverage state: Latest published research available

Generate a fresh DGX analysis

Our latest published analysis: DGX rated Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · DGX

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All DGX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on DGX

Frequently asked questions